Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yihuo + Jin Bifid
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Yihuo + Jin Bifid is a combination probiotic therapy consisting of two distinct products: Yihuo (containing *Clostridium butyricum*) and Jin Bifid (also known as Gold Bifidum, containing *Bifidobacterium longum*, *Lactobacillus acidophilus*, and *Enterococcus faecalis*). This combination is being evaluated in a Phase II clinical trial led by Sun Yat-sen University for the prevention and treatment of diarrhea in patients with HER2-positive breast cancer receiving small-molecule tyrosine kinase inhibitors (TKIs) such as pyrotinib or neratinib. The mechanism involves the restoration of gut microbiota diversity and the stabilization of the intestinal mucosal barrier, which are typically compromised by TKI-induced toxicity. By replenishing beneficial bacteria and producing short-chain fatty acids like butyrate, the therapy aims to improve patient quality of life and treatment compliance.
- Brand names
- YihuoJin BifidGold Bifidum
- Other names
- Clostridium butyricum + Bifidobacterium longum + Lactobacillus acidophilus + Enterococcus faecalis
Beyond the preview
Go deeper on Yihuo + Jin Bifid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yihuo + Jin Bifid.